source
- Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeranModerna chief executive Stéphane Bancel said the company will move quickly to obtain FDA approval for its experimental melanoma therapy intismeran after a Phase 3 trial showed positive results. Th…
- Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loomTwo companies, Taysha Gene Therapies and Neurogene, are nearing the final stage of development for gene therapies targeting Rett syndrome, a rare neurodevelopmental disorder with limited treatment…